Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q
28 nov. 2022 16h47 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing...
Vivos Therapeutics Provides Update on Revenue Recognition Review
22 nov. 2022 07h30 HE
|
Vivos Therapeutics, Inc
Detailed Analysis Finds Minimal Impact on Prior Financial Results;No Previously Reported Revenue to be Lost Previously Reported First Quarter 2022 Revenue Expected to Increase Approximately $200,000;...
Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
26 août 2022 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing...
Vivos Therapeutics Provides Update on Second Quarter Earnings Delay
22 août 2022 16h05 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos”) is providing an update on the delay in announcing its second quarter 2022 financial results. ...
Vivos Therapeutics to Reschedule Second Quarter 2022 Financial Results Conference Call
15 août 2022 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Schedules Second Quarter 2022 Financial Results Conference Call
09 août 2022 08h00 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Announces Exclusive Distribution Agreement with GM Instruments, Ltd. for the U.S. and Canada
29 juin 2022 08h00 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., June 29, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-stage medical technology company focused on developing innovative...
Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea
14 juin 2022 08h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-generating medical technology company focused on developing...
Vivos Therapeutics to Present at Upcoming SLEEP 2022 Annual Meeting
26 mai 2022 08h00 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., May 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a medical technology company focused on developing and commercializing a...
Vivos Therapeutics Reports First Quarter 2022 Financial Results and Operational Update
16 mai 2022 16h05 HE
|
Vivos Therapeutics, Inc
First Quarter Appliance Revenue Increased 19% Year-Over-Year Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., May 16, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics,...